Pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) and other regulations, if applicable, Marksans Pharma has enclosed the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30, 2026 approved by the Board of Directors of the Company at its Meeting held today. i.e. August 12, 2026 along with Limited Review Reports therein. Pursuant to Regulation 33 of the Listing Regulations as amended, they declared that MSKA & Associates LLP, Chartered Accountants, the Statutory Auditors of the Company have submitted the Limited Review Reports for Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30, 2026 with an unmodified opinion. The aforementioned information is also available on the website of the Company at http://www.marksanspharma.com/quarterly-results.html The meeting commenced at 10:50 am and concluded at 12:10 pm.
The above information is a part of company's filings submitted to BSE.
